[PEGS 2023] Comprehensive & Fit-For-Purpose Solutions to Enable Drug Development for Cytokine Targets

[PEGS 2023] Comprehensive & Fit-For-Purpose Solutions to Enable Drug Development for Cytokine Targets
File Name/Number:
PEGS

Year:
2023


Interleukins are known for their involvement in functioning of both the adaptive and innate immune systems. Interleukins direct immune cells to divide and differentiate and are classied as either pro-inflammatory or anti-inflammatory. Interleukins and their receptors are well-validated targets for therapeutic intervention in immuno-oncology and for a variety of disorders, such as psoriatic arthritis, Crohn’s disease, and many other indications. Examples of interleukins that are current targets for therapeutic intervention with marketed drugs include, IL-2, IL-6, IL-4/IL-13, IL-17, and IL-23.